PROCEPT BioRobotics Schedules Fourth Quarter Financial Results
PROCEPT BioRobotics (NASDAQ: PRCT), a pioneering company in surgical robotics focused on enhancing patient care in urology, has announced that it will disclose its financial results for the fourth quarter of 2024 after the market closes. This highly anticipated report is set for release on February 25, 2025, with a conference call hosted by the management team at 4:30 p.m. Eastern Time.
Conference Call Participation Details
Investors seeking to listen to the conference call can easily access it through the dedicated webcast link provided by the company. The live audio will offer insights into PROCEPT’s financial performance and future strategies, which are vital for both current and prospective investors. Additionally, the meeting will be an opportunity for stakeholders to engage directly with the management team, promoting transparency and trust.
PROCEPT BioRobotics' Upcoming Conference Presentations
The company will also take part in significant industry gatherings. Management is scheduled to present at the esteemed TD Cowen 45th Annual Healthcare Conference on March 4 and at the 2025 Leerink Partners Healthcare Conference on March 11. These events are pivotal for showcasing PROCEPT BioRobotics’ commitment to innovation and patient care advancements in urology.
Webcast Availability
A live webcast of each of these events will be accessible on the “Investors” section of PROCEPT BioRobotics' website. After the presentations, archived recordings will remain available for replay, ensuring that all interested parties can access the information at their convenience, reinforcing the company’s commitment to investor accessibility.
About PROCEPT BioRobotics
Founded with a vision to improve patient treatment processes, PROCEPT BioRobotics focuses on developing state-of-the-art surgical robotics. The company has made significant strides with its AQUABEAM and HYDROS Robotic Systems. Notably, the HYDROS system stands as the only AI-Powered robotic technology offering Aquablation therapy, a revolutionary treatment designed for men experiencing lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). BPH is a prevalent condition affecting around 40 million men in the United States alone.
Transformative Technology for Urology
Aquablation therapy, developed by PROCEPT BioRobotics, is engineered to provide effective, safe, and durable results, irrespective of the patient's prostate size or the surgeon's skill level. This innovative approach is backed by a robust collection of clinical research, including over 150 peer-reviewed publications that highlight its benefits and clinical advantages.
Contact Information for Investors
For any inquiries, the Investor Relations contact is Matt Bacso, who serves as the VP of Investor Relations and Business Operations. He can be reached via email for further information or specific investor-related queries.
Frequently Asked Questions
When will PROCEPT BioRobotics announce its financial results?
The financial results for the fourth quarter will be reported after market close on February 25, 2025.
How can investors access the conference call?
Investors can listen to the conference call via the webcast link available on the company’s investor relations page.
What are the key conferences PROCEPT BioRobotics will attend?
PROCEPT will participate in the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference.
What technology does PROCEPT BioRobotics specialize in?
PROCEPT specializes in surgical robotics, focusing on solutions that enhance urological patient care, including the AQUABEAM and HYDROS robotic systems.
Who can be contacted for investor relations inquiries?
Matt Bacso, the VP of Investor Relations and Business Operations, is the point of contact for investor relations.
